Irina Rebin

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Carrière

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Formation

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Featured

Actualités et publications récentes

View Irina's insights

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Research and innovation as a competitive advantage – Legal framework for Life Sciences made in Europe

27 janvier 2026

par Irina Rebin

Sciences de la vie et Santé

Life Sciences Made in Europe – The European Commission’s Life Sciences Strategy 2030

27 janvier 2026

In-depth analysis

par Irina Rebin

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Adoption of Commission Implementing Regulation (EU) 2025/2086: New Rules on the Joint Clinical Assessment of Medical Devices and In Vitro Diagnostic Medical Devices

23 janvier 2026

Briefing

par Irina Rebin et Daniel Dietrich

Cliquer ici pour en savoir plus

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs